Notice of Annual General Meeting of Vitrolife AB (publ)

The Annual General Meeting of Vitrolife AB (publ) will take place on Thursday April 19, 2012, at 5 p.m. in the company’s premises at Gustaf Werners gata 2 in Gothenburg. Notice of attendance at the Annual General Meeting shall be given no later than Friday, April 13, 2012, at 12 noon.

Shareholders wishing to participate at the Annual General Meeting shall notify the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83, by fax +46 31 721 80 99 or by e-mail aahlqvist@vitrolife.com. Name/business name, personal identification number/ company registration number (or the equivalent), address, telephone number, number of shares, details of any advisors and where appropriate details of a representative or proxy must be stated in the notification. A proxy form in Swedish for shareholders wishing to be represented by proxy will be found on www.vitrolife.com.

Shareholders that have their shares registered in the name of a nominee must temporarily record their shares in the share register kept by Euroclear Sweden AB in their own names to be able to attend the General Meeting. Such registration must be carried out no later than Friday, April 13, 2012.

The following proposals will be amongst those presented at the Annual General Meeting:

• Dividend of SEK 0.60 per share and Tuesday, April 24, 2012, as the record date for the dividend.

• The Election Committee proposes that the number of members of the Board of Directors shall be six. Patrik Tigerschiöld, Fredrik Mattsson, Maris Hartmanis, Tord Lendau and Barbro Fridén are proposed for re-election as Board members and Carsten Browall is proposed as a new member of the Board. The Board member Madeleine Olsson-Eriksson has declined re-election. As Chairman of the Board, the committee proposes re-election of Patrik Tigerschiöld. Remuneration to the Board of Directors is proposed to be a total of SEK 770,000, of which SEK 220,000 is to be allocated to the Chairman of the Board and SEK 110,000 to each of the other Board members. The amounts include remuneration for committee work. The proposal means that Board fees are unchanged.

• Authorization for the Board to resolve to issue new shares up until the next Annual General Meeting.

• Authorization for the Board to make a decision on the acquisition of the company’s own shares during the period up until the next Annual General Meeting.

Attachment: Full notice

Gothenburg, March 19, 2012
VITROLIFE AB (publ)
The Board

Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Board, phone 46 8 614 00 20

Mikael Engblom, CFO, phone +46 31 721 80 14

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on March 19, at 12:00 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife is a global biotechnology/medical device Group that works in the areas of Fertility and Transplantation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. The Transplantation product area works with solutions and systems for assessing and preserving organs outside the body, so as to be able to select usable organs and keep them in optimal condition pending transplantation.

Vitrolife today has approximately 220 employees and its products are sold in almost 90 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

_________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.

Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags: